;

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Finance > Merck to acquire Verona Pharma for $10 billion

Finance

Merck to acquire Verona Pharma for $10 billion

Published by Global Banking and Finance Review

Posted on July 9, 2025

Featured image for article about Finance

(Reuters) -Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's presence in respiratory treatments as it readies for the patent expiry of its blockbuster cancer drug.

(Reporting by Christy Santhosh in Bengaluru; Editing by Sriraj Kalluvila)

More from Finance

Explore more articles in the Finance category

Fitch places Euroclear Bank on 'rating watch negative' over EU's Russian asset plans

Oil rises over 1% as Trump's Venezuela blockade stokes uncertainty

UK to provide financial support to save its last ethylene plant

Doctors in England begin five-day walkout during flu surge

Polestar secures $600 million loan from majority owner Geely Holding

Couple, man who died trying to stop Bondi Beach attackers praised for heroic efforts

Analysis-Consumer goods firms cut CEO tenures short in push for growth

BAE Systems halves stake in Kazakh carrier Air Astana

Tesla ramps up battery cell investments at German gigafactory

Stellantis says EU proposals fall short on auto industry's energy transition needs

OpenAI taps former UK finance minister Osborne to lead global Stargate expansion

US threatens countermeasures on European service providers after EU fines

View All Finance Posts